Skip to main content

SYSTEMATIC REVIEW article

Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1405261
This article is part of the Research Topic Updates in Ocular Therapeutics and Surgery, Volume III View all 10 articles

The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: A systematic review and meta-analysis

Provisionally accepted
Chang-zhu He Chang-zhu He 1Song-Jie Lu Song-Jie Lu 1*Zhao-Jun Zeng Zhao-Jun Zeng 1*Jun-Qiao Liu Jun-Qiao Liu 1*Qin Qiu Qin Qiu 1*Fu-Li Xue Fu-Li Xue 1*Yu He Yu He 2*
  • 1 Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 2 Chengdu Integrated TCM and Western Medical Hospital, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Background: The intraocular injections of anti-vascular endothelial growth factor (anti-VEGF) demonstrates significant efficacy in inhibiting the formation of ocular neovascularization in neovascular glaucoma (NVG). Ahmed glaucoma valve implantation (AGVI) is extensively employed for the management of diverse glaucoma types.Objective: To further evaluate the efficacy and safety of anti-VEGF combined with AGVI in the treatment of neovascular glaucoma. Methods: A thorough search for randomized controlled trials (RCTs) was conducted across eight databases: PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed, and VIP. The search period was set from the inception of each database until March 2, 2024, to identify RCTs investigating the effectiveness and safety of combining AGVI with anti-VEGF therapy for NVG. We used the Cochrane Risk of Bias Assessment Tool to evaluate the quality of the literature and performed statistical analysis using Stata 15.0 software. Results: Fourteen RCTs were included in this study. Compared with AGVI alone, the combination of anti-VEGF drugs and AGVI can reduce postoperative intraocular pressure (IOP) at 1 week [WMD = -4.

    Keywords: Ahmed glaucoma valve implantation1, Anti-vascular endothelial growth factor2, Neovascular glaucoma3, meta-analysis4, Systematic review5 03, 95% CI (-5.73, -2.34), P＜0.001]

    Received: 22 Mar 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 He, Lu, Zeng, Liu, Qiu, Xue and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Song-Jie Lu, Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Zhao-Jun Zeng, Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Jun-Qiao Liu, Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Qin Qiu, Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Fu-Li Xue, Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Yu He, Chengdu Integrated TCM and Western Medical Hospital, Chengdu, 610041, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.